Amycretin: Could the Next Generation of GLP-1 and Amylin Peptides Change Weight-Loss Treatment?
The modern weight-management revolution has largely been driven by one hormone pathway: GLP-1. Semaglutide demonstrated how dramatically GLP-1 receptor activation could affect appetite, body weight and metabolic health. Tirzepatide then expanded the concept by simultaneously targeting GIP and GLP-1 receptors. Retatrutide is pushing the science further by investigating combined GIP, GLP-1 and glucagon receptor activation. […]
Continue Reading